Vaxcyte Raises Executive Severance Multipliers in Amended Agreements

Reuters2025-12-20

Vaxcyte Raises Executive Severance Multipliers in Amended Agreements

Vaxcyte Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including CEO Grant Pickering, President and CFO Andrew Guggenhime, COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal. Effective December 31, 2025, the base salary severance multiplier and COBRA severance multiplier in the event of a Qualifying Termination will increase to 1.5x for Mr. Pickering and 1.0x for Messrs. Guggenhime, Wassil, and Dhaliwal. In the event of a change in control (CIC) Qualifying Termination, the base salary severance multiplier, target annual bonus severance multiplier, and COBRA severance multiplier will increase to 2.0x for Mr. Pickering and 1.5x for Messrs. Guggenhime, Wassil, and Dhaliwal. These adjustments bring the severance components more in line with peer group levels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649094-25-000116), on December 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592019721?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-20 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592019721","market":"fut","top_or_hot":-1,"title":"Vaxcyte Raises Executive Severance Multipliers in Amended Agreements","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Raises Executive Severance Multipliers in Amended Agreements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including CEO Grant Pickering, President and CFO Andrew Guggenhime, COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal. Effective December 31, 2025, the base salary severance multiplier and COBRA severance multiplier in the event of a Qualifying Termination will increase to 1.5x for Mr. Pickering and 1.0x for Messrs. Guggenhime, Wassil, and Dhaliwal. In the event of a change in control (CIC) Qualifying Termination, the base salary severance multiplier, target annual bonus severance multiplier, and COBRA severance multiplier will increase to 2.0x for Mr. Pickering and 1.5x for Messrs. Guggenhime, Wassil, and Dhaliwal. These adjustments bring the severance components more in line with peer group levels.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649094-25-000116), on December 19, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte Raises Executive Severance Multipliers in Amended Agreements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte Raises Executive Severance Multipliers in Amended Agreements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-20 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vaxcyte Raises Executive Severance Multipliers in Amended Agreements\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vaxcyte Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including CEO Grant Pickering, President and CFO Andrew Guggenhime, COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal. Effective December 31, 2025, the base salary severance multiplier and COBRA severance multiplier in the event of a Qualifying Termination will increase to 1.5x for Mr. Pickering and 1.0x for Messrs. Guggenhime, Wassil, and Dhaliwal. In the event of a change in control (CIC) Qualifying Termination, the base salary severance multiplier, target annual bonus severance multiplier, and COBRA severance multiplier will increase to 2.0x for Mr. Pickering and 1.5x for Messrs. Guggenhime, Wassil, and Dhaliwal. These adjustments bring the severance components more in line with peer group levels.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649094-25-000116), on December 19, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLlb1SF:1","article_id":"2592019721","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592019721","pubTimestamp":1766178709,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vaxcyte Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including CEO Grant Pickering, President and CFO Andrew Guggenhime, COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal. Effective December 31, 2025, the base salary severance multiplier and COBRA severance multiplier in the event of a Qualifying Termination will increase to 1.5x for Mr. Pickering and 1.0x for Messrs. Guggenhime, Wassil, and Dhaliwal. In the event of a change in control  Qualifying Termination, the base salary severance multiplier, target annual bonus severance multiplier, and COBRA severance multiplier will increase to 2.0x for Mr. Pickering and 1.5x for Messrs. Guggenhime, Wassil, and Dhaliwal. These adjustments bring the severance components more in line with peer group levels.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","PCVX":"Vaxcyte, Inc.","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"Vaxcyte在修订后的协议中提高了高管遣散费乘数","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":0.9},"content_text":"Vaxcyte Raises Executive Severance Multipliers in Amended Agreements\n    \n\n        Vaxcyte Inc. has amended its Executive Change in Control and Severance Agreements with key executives, including CEO Grant Pickering, President and CFO Andrew Guggenhime, COO Jim Wassil, and Chief Technical Operations Officer Harpreet Dhaliwal. Effective December 31, 2025, the base salary severance multiplier and COBRA severance multiplier in the event of a Qualifying Termination will increase to 1.5x for Mr. Pickering and 1.0x for Messrs. Guggenhime, Wassil, and Dhaliwal. In the event of a change in control (CIC) Qualifying Termination, the base salary severance multiplier, target annual bonus severance multiplier, and COBRA severance multiplier will increase to 2.0x for Mr. Pickering and 1.5x for Messrs. Guggenhime, Wassil, and Dhaliwal. These adjustments bring the severance components more in line with peer group levels.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001649094-25-000116), on December 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592019721","isCrawlerRequest":true}